论文部分内容阅读
Objective To explore the clinical pathological features and immunophenotypes of cervical intraepithelial neoplasia(CIN).Methods The protein expression of p16, p53, Bcl-2, and c-erb B-2 in 59 cases of CIN, 20 cases of cervical squamous cell carcinoma, and 20 cases of normal cervical tissues were tested using immunohistochemistry staining.Results The expression rates of p16, p53, Bcl-2, and c-erb B-2 in CIN tissues were 76.3%(45/59), 28.85(17/59), 61.0%(36/59), and 40.0%(23/59), respectively. The expression rates of p16, p53, Bcl-2, and c-erb B-2 in cervical squamous cell carcinoma tissues were 60.0%(12/20), 60.0%(12/20), 75.0%(15/20), and 65.0%(13/20), respectively. The expression rates of p16, p53, Bcl-2, and c-erb B-2 in normal cervical tissues were 0.0%(0/20), 0.0%(0/20), 35.0%(7/20), 0.0%(0/20), respectively. In comparison to normal tissues, the differential expressions of p16, p53, and Bcl-2 in squamous cell carcinoma and CIN were statistically significant(P <0.001), whereas the difference between the squamous cell carcinoma and CIN was not significant(P >0.05). In comparison to normal tissues, the differential expressions of c-erb B-2 and p53 in squamous cell carcinoma and CIN were statistically significant(P >0.05). The differential expressions of Bcl-2, c-erb B-2, and p53 in CIN 3 were statistically significant in comparison to CIN 1 and CIN 2(P <0.05). Conclusion Overexpression of Bcl-2 occurs early in the development of cervical cancer, whereas p16 and c-erb B-2 overexpression are markers for cell malignancy. The expression of p53 is correlated with the development of cervical cancer.
Objective To explore the clinical pathological features and immunophenotypes of cervical intraepithelial neoplasia (CIN). Methods The protein expression of p16, p53, Bcl-2, and c-erb B-2 in 59 cases of CIN, 20 cases of cervical squamous cell carcinoma , and 20 cases of normal HPV tissues were tested using immunohistochemistry staining. Results of the expression rates of p16, p53, Bcl-2, and c-erb B-2 in CIN tissues were 76.3% (45/59), 28.85 59%, 61.0% (36/59), and 40.0% (23/59), respectively. The expression rates of p16, p53, Bcl-2, and c-erb B-2 in cervical squamous cell carcinoma tissues were 60.0% (12/20), 60.0% (12/20), 75.0% (15/20), and 65.0% (13/20), respectively. The expression rates of p16, p53, Bcl-2, and c-erb B -2 in normal tissues were 0.0% (0/20), 0.0% (0/20), 35.0% (7/20), 0.0% (0/20), respectively. of p16, p53, and Bcl-2 in squamous cell carcinoma and CIN were statistically significant (P <0.001), the the di The differential expressions of c-erb B-2 and p53 in squamous cell carcinoma and CIN were statistically significant (P> 0.05). The differential expressions of Bcl-2, c-erb B-2, and p53 in CIN 3 were statistically significant in comparison to CIN 1 and CIN 2 (P <0.05). Conclusion Overexpression of Bcl-2 occurs early in the development of cervical cancer, while p16 and c-erb B-2 overexpression are markers for cell malignancy. The expression of p53 is correlated with the development of cervical cancer.